Praxis Precision Medicines, Inc.

Praxis Precision Medicines, Inc.

PRAXNYSE / NASDAQHealthcareSmall cap

$300.43-$10.47 (-3.4%)

Last close · Data as of Nov 20, 2026

Market cap
$7.4B
P/E
-24.3x
EV / EBITDA
-21.5x
Revenue
$0.00
ROCE
-37.1%

+83.1% over the last year

Praxis Precision Medicines, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
+13.6%
3M
-17.6%
6M
-10.5%
1Y
+83.1%
5Y
Hidden
  • This period includes a one-day price step on 16 Oct 2025 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.

52-week range

Day change -$10.47 (-3.4%) from $311 to $300 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in PRAX, bought on each weekday since 2021.

News & filings

What Praxis Precision Medicines filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 303 million US dollars in fiscal 2025.

Strengths (1)

  • Current assets are more than ten times current liabilities.
  • Revenue is too small for margins and growth rates to be read, so those points are not shown.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States.

Read moreShow less

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. The company's platforms include Cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and Solidus to discover and develop antisense oligonucleotide. It also develops ulixacaltamide, a small molecule inhibitor of T-type calcium channels that in NDA for the treatment of essential tremor; relutrigine, a small molecule, which is in NDA for the treatment of SCN2A- and SCN8A-developmental and epileptic encephalopathies (DEE), as well as in Phase 3 trial for broad DEEs; vormatrigine, a small molecule targeting the hyperexcitable state of sodium-channels in the brain that is in Phase 3 trial for the treatment of adjunctive focal epilepsy, as well as in Phase 2 trial for monotherapy focal epilepsy; and Elsunersen, a clinical-stage ASO designed to selectively decrease SCN2A gene expression, which is in Phase 3 trial for the treatment of SCN2A-DEE. In addition, the company is developing product candidates in pre-clinical trial comprising PRAX-020 to treat KCNT1; PRAX-080 that targets PCDH19 mosaic expression disorders; PRAX-090 for targeting SYNGAP1 loss-of-function; and PRAX-100 that targets SCN2A LoF mutations. It has a cooperation and license agreement with RogCon Inc.; and a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc. The company was formerly known as EpiPM Therapeutics, Inc. and changed its name to Praxis Precision Medicines, Inc. in October 2016. Praxis Precision Medicines, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Sector
Healthcare
Shares outstanding
25.2M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$7.4B
P/E
-24.3x
P/B
8.4x
EV / EBITDA
-21.5x
52-week high
$386.33
52-week low
$164.09

Profitability

ROE
-34.5%
ROCE
-37.1%
ROIC
-49.5%
ROA
-32.3%

Growth

Revenue
$0.00
Revenue growth, 1Y
-100.0%
Net profit growth, 1Y
65.9%
Free cash flow
-$249.1M

Solvency

Current ratio
10.22
Debt / Equity
0.00
Debt / Assets
0.00
CFO / Net profit
0.82
Cash / Market cap
4.8%

Revenue and net profit

Revenue fell 100.0% in FY2025; net profit is the dashed line.

Praxis Precision Medicines, Inc. revenue and net profit by fiscal year
Praxis Precision Medicines, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$0.00-$214.0M
FY2023$2.4M-$123.3M
FY2024$8.6M-$182.8M
FY2025$0.00-$303.3M

Cash flows

FY2025: -$249.1M from operations, -$249.1M free after investment (dashed).

Praxis Precision Medicines, Inc. operating and free cash flow by fiscal year
Praxis Precision Medicines, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$185.0M-$185.5M
FY2023-$111.1M-$111.2M
FY2024-$131.8M-$131.8M
FY2025-$249.1M-$249.1M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$0.00-100.0%1Y
EBITDA
-$326.1M
Net profit
-$303.3M
Cash from operations
-$249.1M
Free cash flow
-$249.1M
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$0.00-$326.1M-$303.3M-$249.1M-34.5%-100.0%+65.9%

Monthly returns

Month-by-month returns of PRAX across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$937.9M
Liabilities$59.8M
Equity$878.1M
Paid-in capital$2.0B
Retained earnings-$1.1B

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; PRAX highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

EV / Sales, for the companies without earnings

Not shown (no positive earnings and no EV / Sales): Praxis Precision Medicines, Inc., Nuvalent, Inc., Vaxcyte, Inc., Apogee Therapeutics, Inc., Spyre Therapeutics, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Praxis Precision Medicines, Inc.PRAXthis company$7.4B-24.3x8.4x-34.5%-21.5x
ImmunityBio, Inc.IBRX$7.6B-21.7x-15.3x70.2%-36.1x
Nuvalent, Inc.NUVL$7.4B-17.5x5.9x-34.1%—
HealthEquity, Inc.HQY$7.2B33.4x3.4x10.2%16.1x
Oscar Health, Inc.OSCR$7.1B-16.1x7.3x-45.3%—
Vaxcyte, Inc.PCVX$7.0B-9.2x2.6x-28.5%-7.8x
Apogee Therapeutics, Inc.APGE$6.9B-26.8x7.6x-28.3%-23.7x
Spyre Therapeutics, Inc.SYRE$6.8B—9.5x-21.7%—
Arcellx, Inc.ACLX$6.7B-29.4x16.7x-56.9%-30.2x
Peer median—-17.5x6.6x-28.4%-23.7x

Year-to-date ROI

PRAX since 1 January, against earlier years.

Historical volatility

PRAX's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Praxis Precision Medicines, Inc. operating margin by fiscal year
Praxis Precision Medicines, Inc. operating margin by fiscal year
DateOperating margin
FY2023-5158.0%
FY2024-2341.1%
FY2025—
LineFY2025
Operating expensesOperating Expense$326.2M
Research and developmentResearch And Development$267.1M
Total expensesTotal Expenses$326.2M
Pretax incomePretax Income-$303.3M

Learn while you research

Academy chapters picked for Praxis Precision Medicines, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →